Researcher
Hans Wildiers
- Disciplines:Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Laboratory of Experimental Oncology (Division)
Member
From1 Oct 2005 → Today
Projects
1 - 10 of 27
- Breast cancer projectFrom1 Jan 2024 → TodayFunding: Other federal public and semi-governmental institutions
- Real-time qPCR platform enhancing research activities within the Laboratory of Experimental Oncology and the Laboratory of Experimental RadiotherapyFrom1 Jan 2023 → TodayFunding: BOF - scientific equipment program
- Building a large blood biobank of patients with new breast cancer diagnosis for future researchFrom1 Jan 2022 → 5 Jun 2023Funding: Other federal public and semi-governmental institutions
- UPTIDER (UZ/KU Leuven Program for post-mortem Tissue Donation to Enhance Research), a unique setting to unravel treatment resistance and disease progression in patients with breast cancer.From1 Oct 2021 → TodayFunding: BOF - projects
- The impact of coaching on quality of life of older cancer patientsFrom27 Sep 2021 → 31 Aug 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- Streamlined Geriatric and Oncological evaluation based on IC Technology for holistic patient-oriented healthcare management for older multimorbid patientsFrom1 Apr 2021 → TodayFunding: H2020 - Health, demographic change and wellbeing
- Mechanisms involved in metastasis of luminal breast cancerFrom1 Mar 2021 → 28 Feb 2022Funding: Foundations, funds and other with scientific goal
- The MBC biobank collection.From1 Dec 2020 → 31 Oct 2021Funding: Other federal public and semi-governmental institutions
- Risk prediction and modeling of cancer therapy related cardiotoxicityFrom1 Oct 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Novel biomarkers in the risk stratification, surveillance and treatment of young breast cancer patients and germline carriers of pathogenic variants in TP53.From1 Sep 2020 → 13 Feb 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
Publications
31 - 40 of 475
- Biologic profile to predict overall survival in non-metastatic breast cancer: A latent class analysis on aging biomarkers(2023)
Authors: Cindy Kenis, Patrick Neven, Sigrid Hatse, Hans Wildiers
- A multicenter randomized controlled trial (RCT) for the effectiveness of comprehensive geriatric assessment (CGA) with extensive patient coaching on quality of life (QoL) in older patients with solid tumors receiving systemic therapy: G-oncoCOACH study(2023)
Authors: Cindy Kenis, Johan Flamaing, Koen Milisen, Hans Wildiers
- Capturing age-related changes in the tumor microenvironment of luminal breast cancer using the multiplex immunohistochemistry technique, MILAN.(2023)
Authors: Yentl Lambrechts, Maxim De Schepper, Tatjana Geukens, Hanne Vos, Julie Messiaen, Patrick Neven, Christine Desmedt, Francesca Bosisio, Frederik De Smet, Sigrid Hatse, et al.
- An age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01,-02, and-03(2023)
Authors: Hans Wildiers
- Machine Learning Algorithm to Estimate Distant Breast Cancer Recurrence at the Population Level with Administrative Data(2023)
Authors: Hava Izci, Hans Wildiers, Patrick Neven
Pages: 559 - 568 - Mortality and Major Adverse Cardiac Events in Patients With Breast Cancer Receiving Radiotherapy: The First Decade(2023)
Authors: Johanna Jacobs, Caroline Weltens, Jens-Uwe Voigt, Hans Wildiers, Patrick Neven, Jan A Staessen, Lucas Van Aelst
- A randomized controlled trial of hand/foot-cooling by hilotherapy to prevent oxaliplatin-related peripheral neuropathy in patients with malignancies of the digestive system(2023)
Authors: Annemarie Coolbrandt, Annouschka Laenen, Hans Wildiers, Chris Verslype, Jeroen Dekervel, Eric Van Cutsem
- Antinuclear antibodies in individuals with COVID-19 reflect underlying disease: Identification of new autoantibodies in systemic sclerosis (CDK9) and malignancy (RNF20, RCC1, TRIP13)(2023)
Authors: Xavier Bossuyt, Glynis Frans, Nick Geukens, Sebastien Carpentier, Sabine Tejpar, Hans Wildiers, Daniel Engelbert Blockmans, Ellen De Langhe, Pieter Vermeersch, Rita Derua
- Can ADCs broaden the treatment landscape of metastatic ER+/HER2- breast cancer resistant to CDK4/6 inhibition?(2023)
Authors: Karen Van Baelen, Christine Desmedt, Hans Wildiers, Patrick Neven
Pages: 269 - Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer (vol 33, pg 769, 2022)(2023)
Authors: François Richard, Chantal Van Ongeval, Maxim De Schepper, Ann Smeets, Hans Wildiers, Patrick Neven, Christine Desmedt
Pages: 326 - 326